SAN.PA - Sanofi
| Previous Close | 81.42 |
| Open | 81.50 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 81.17 - 83.32 |
| 52 Week Range | 71.74 - 83.32 |
| Volume | 8,017,591 |
| Avg. Volume | 2,329,796 |
| Market Cap | 105.888B |
| Beta (3Y Monthly) | 0.44 |
| PE Ratio (TTM) | 29.24 |
| EPS (TTM) | 2.85 |
| Earnings Date | Oct 31, 2019 |
| Forward Dividend & Yield | 3.07 (3.77%) |
| Ex-Dividend Date | 2019-05-09 |
| 1y Target Est | 82.62 |
- Yahoo Finance Video
Top Trending: Abbott and Sanofi team up to help diabetes patients, Boeing’s board expected to reconsider engineering
Top Trending: Abbott and Sanofi team up to help diabetes patients, Boeing’s board expected to reconsider engineering, and NBA's Raptors to introduce sports hijab for women.
- Investor's Business Daily
Stocks Reverse Lower On Trade Fears, But Small Caps Lose Less
Stock indexes reversed lower Friday afternoon, as the market for a second straight day seemed unable to hold early advances. The S&P; 500 today and other indexes fell sharply at 1:15 p.m. ET.
- Bloomberg
Carcinogen in Zantac Leads to Another Shipment Halt, Recall
(Bloomberg) -- A global effort to remove gastrointestinal medication tainted with a potential carcinogen from the market gained momentum, as one of India’s largest generic drugmakers halted shipments to customers worldwide and Italy ordered a recall of some medicine that originated in India.Dr. Reddy’s Laboratories Ltd. said it is suspending all distribution of its ranitidine, the generic version of the Sanofi stomach drug Zantac, as a precautionary measure. The company expects “to provide an update in the coming days,” said spokeswoman Lori McCreary in an email.Separately, the Italian Drug Agency said in a statement it was ordering a recall of all versions of Zantac with active ingredient made by the India-based firm Saraca Laboratories Ltd. Italian regulators also banned the use of some types of Zantac produced by other pharmaceutical companies pending analysis of the drugs.U.S. and European Union regulators said last week they were investigating the discovery of the carcinogen NDMA, or N-Nitrosodimethylamine, in branded and generic Zantac. The regulators said they hadn’t ascertained how the drugs came to be contaminated. In the U.S., the Food and Drug Administration has so far left the drugs on the market.NDMA was also detected in a commonly prescribed class of blood-pressure drugs, leading to the recall of millions of pills in 30 countries beginning in July of last year. In addition to the Italian drug agency, Germany’s drug regulator indicated earlier this week there were wider recalls of ranitidine made with active ingredient from Saraca in Europe. Saraca supplies larger drugmakers that make the pills sold to patients.Health officials in Canada have asked all makers of ranitidine to stop distribution of the heartburn treatment in that country.Novartis AG’s generic-drug unit, Sandoz, halted global distribution on Wednesday of its generic Zantac, known as ranitidine. Brand-name Zantac maker Sanofi hasn’t halted distribution of the drug or any of its other ranitidine products outside of Canada. About two dozen generic drugmakers are FDA-approved to sell their own versions of prescription and over-the-counter Zantac in the U.S., including Sandoz and Dr. Reddy’sBloomberg News has reported on how poor quality controls and efforts to conceal manufacturing problems from the FDA have complicated oversight of overseas drug producers.As regulators deal with the Zantac investigation, the worldwide recall of tainted blood-pressure pills known as angiotensin II receptor blockers, or ARBs, is still widening. On Thursday, India-based Torrent Pharmaceuticals Ltd., expanded a recall of the ARB called losartan, which has been found to be contaminated with a different potential carcinogen called NMBA.(Updates with Italian recall starting in first paragraph.)To contact the reporter on this story: Anna Edney in Washington at aedney@bloomberg.netTo contact the editors responsible for this story: Drew Armstrong at darmstrong17@bloomberg.net, Timothy AnnettFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
- GlobeNewswire
Sanofi : CHMP recommends approval of Dupixent® (dupilumab) for severe chronic rhinosinusitis with nasal polyposis
September 20, 2019 – The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Dupixent® (dupilumab) in a third indication. The CHMP recommended Dupixent be approved as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe chronic rhinosinusitis with nasal polyposis (CRSwNP) for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. If approved, Dupixent would be the first biologic medicine available in the European Union (EU) to treat these patients.
- Reuters
Factbox: Britain's insulin providers prepare for Brexit fallout
With Britain sourcing the vast majority of the insulin needed by its 1 million diabetics from overseas, its biggest providers have had to restructure their supply chains in case a chaotic Brexit disrupts the normal arteries of trade. Below are some of the steps Novo Nordisk, Eli Lilly and Sanofi have taken to prepare for Britain's departure from the European Union on Oct. 31. - All three firms have increased the amount of insulin they are holding inside the country in case a no-deal Brexit leads to customs checks and lengthy delays at Britain's biggest ports of Dover and Folkestone.
- GlobeNewswire
Sanofi: information concerning the total number of voting rights and shares, August 2019
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and.
- Yahoo Finance
Abbott, Sanofi to help diabetes patients with technology team-up
Abbott and Sanofi announce a new collaboration to help diabetes patients.
- GlobeNewswire
Sanofi and Abbott partner to integrate glucose sensing and insulin delivery technologies to help change the way diabetes is managed
– September 16, 2019 – Sanofi and Abbott are partnering to integrate glucose sensing and insulin delivery technologies that would help to further simplify how people with diabetes manage their condition. The two companies will take an innovative approach to connected care by developing tools that combine the revolutionary FreeStyle Libre technology with insulin dosing information for future smart pens, insulin titration apps and cloud software.
- Investor's Business Daily
Popular Sanofi Heartburn Drug Could Contain Carcinogens, FDA Says
A commonly used heartburn medicine from Sanofi, known as Zantac, could contain cancer-causing substances, the Food and Drug Administration said Friday. Sanofi stock fell a fraction.
- TheStreet.com
FDA Says Sanofi's Zantac Medication Has Impurity That Could Cause Cancer
The FDA isn't calling for consumers to stop taking heartburn relief medicines with ranitidine 'at this time.'
- Benzinga
The Daily Biotech Pulse: Lexicon Snaps Sanofi Diabetes Partnership With $260M Settlement, Celyad Offering, Multiple Sclerosis Conference Gets Underway
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Sept. 10) Ardelyx Inc (NASDAQ: ARDX ) Avedro Inc (NASDAQ: AVDR ...
- Reuters
Sanofi to pay Lexicon $260 mln for terminated partnership
Lexicon Pharmaceuticals Inc said on Tuesday France's Sanofi SA will pay the drugmaker $260 million for the termination of their partnership to develop diabetes drug Zynquista. Under the terms of the settlement, Sanofi will pay $208 million upfront and the remainder within twelve months to Lexicon, which was eligible to receive up to $1.4 billion in milestone payments under the partnership. The four-year partnership was terminated by Sanofi in July after the results of three late-stage studies of Zynquista, which is being developed as an add-on to insulin for diabetic patients.
- Reuters
UPDATE 1-Novo Nordisk to cut insulin prices in the U.S.
Novo Nordisk will offer cheaper insulin to U.S. diabetics, the Danish drugmaker said on Friday, in response to criticism over the high price of the medication and after similar moves by rivals Sanofi and Eli Lilly. President Donald Trump has made high prescription drug prices a top issue in the 2016 presidential campaign and said that drug companies were "getting away with murder". Novo will offer a generic version of its most heavily prescribed insulin drug Novolog, used by about a million U.S. patients, at a 50% discount compared to the current list price, the company said in a statement.
- Motley Fool
Is the FDA Out to Get This $2.9 Billion Diabetes Drug Class?
It’s rejected a pair of drugs in the last six months.
- Moody's
L'Oreal U.S.A. Inc. -- Moody's affirms L'Oréal S.A.'s Prime-1 rating, stable outlook
Moody's Investors Service ("Moody's") has today affirmed the Prime-1 (P-1) short-term Commercial Paper ratings of both L'Oréal S.A. and its US subsidiary L'Oréal U.S.A. Inc. The outlook is stable. The affirmation of L'Oréal's Prime-1 (P-1) short-term Commercial Paper rating reflects the group's strong business profile, solid profitability and very strong credit metrics. Moody's expects the group's growth to continue to outperform the global beauty market.
- Motley Fool
Here's How Emergent BioSolutions Procured a Higher Price Today
The U.S. government wants more of its smallpox vaccine.
- Barrons.com
Sanofi Stock Is a Buy Because of Its Drug Pipeline, Analyst Says
Bernstein initiated coverage on Tuesday with an Outperform rating, saying that the company is well-positioned to succeed over the next few years.
- Simply Wall St.
What Kind Of Investor Owns Most Of Sanofi (EPA:SAN)?
Every investor in Sanofi (EPA:SAN) should be aware of the most powerful shareholder groups. Institutions will often...
- Investor's Business Daily
How To Trade Growth Stocks: The Easy Way To Check And Confirm Institutional Support
The concept of support is not one of the first things you need to understand as an investor, but you will find it a powerful tool once you learn to use it.
- Reuters
UPDATE 2-Novartis takes aim at Roche's star MS drug
Swiss drugmaker Novartis on Friday stepped up its challenge to Roche's multiple sclerosis franchise, highlighting study results for its MS hopeful ofatumumab that could compete with its cross-town rival's drug Ocrevus. Novartis said ofatumumab, already approved as Arzerra to treat leukaemia, reduced annual relapses better than Sanofi's Aubagio in two head-to-head late-stage studies against relapsing forms of MS (RMS). Detailed study results are due at an MS conference in Sweden next month.
- GlobeNewswire
Sanofi : U.S. District Court invalidates Amgen patent claims targeting PCSK9
August 28, 2019 – Sanofi and Regeneron Pharmaceuticals, Inc. announced today that the U.S. District Court for the District of Delaware ruled in their favor and found as a matter of law that Amgen’s asserted patent claims for antibodies targeting PCSK9 (proprotein convertase subtilisin/kexin type 9) are invalid based on lack of enablement. “It has been our longstanding belief that all of Amgen’s asserted U.S. PCSK9 patent claims are invalid, and we are pleased today’s decision reaffirms this,” said Karen Linehan, Executive Vice President and General Counsel, Sanofi.
- Reuters
U.S. judge rules for Regeneron, Sanofi in Amgen cholesterol drug patent fight
The ruling from U.S. District Judge Richard Andrews in Wilmington, Delaware was the latest reversal of fortune in a long-running lawsuit in which Amgen is seeking to stop French drugmaker Sanofi and U.S. biotech Regeneron from selling their drug Praluent. Repatha and Praluent won U.S. approval about two weeks apart in July of 2016.
- Benzinga
Biotech Stock On The Radar: MyoKardia Bets On Precision Medicine For Heart Health
MyoKardia Inc (NASDAQ: MYOK), a thinly traded mid-cap biotech, is on the radar of investors ahead of the company's scheduled presentation at the European Society of Cardiology Congress Aug. 31-Sept. 4 in Paris. The company is scheduled to present 36-week data from the PIONEER-OLE study — an open label extension study of the Phase 2 PIONEER study — that is evaluating its investigational drug and lead product candidate mavacamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy, or oHCM. Patients with oHCM are at an increased risk of heart failure, atrial fibrillation, stroke and death, including sudden cardiac death.
